Opus Genetics Inc (IRD)
Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for inherited retinal diseases (IRDs). Its pipeline includes OPGx-LCA5, which is in a Phase 1/2 clinical trial for LCA5-associated early-onset retinal degeneration, and OPGx-BEST1 for BEST1-related retinal disease. The company’s preclinical programs include OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-CNGB1, each designed to address specific genetic forms of retinal degeneration. Opus Genetics also is developing Phentolamine Ophthalmic Solution for reversal of mydriasis and treatment of presbyopia and dim light or night vision disturbances, along with APX3330 for diabetic retinopathy. Formerly known as Ocuphire Pharma, Inc., the company was founded in 2018 and is headquartered in Durham, North Carolina. The common stock is listed on NASDAQ under the ticker IRD.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IRD
|
$4.69
|
-9.0% Downside
|
Fair
|
$13
|
151.9% Upside
|
Bargain
|
Fair
|
0.0%
|
November 17, 2026
|
43.6x
|
429.3 M
|
376.7 M
|
7.6%
|
77.1%
|
-2.1
|
37.8%
|
